EHC Encompass Health Corporation Common Stock
XNYS
140.54
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
EHC
$140.54
—
What changed
Recent filings, trades and movesKey stats
$140.54
- 52-Week Range
- $92.77 – $143.36
- YTD
- +32.12%
- IV Rank (30D)
- 19.12
- Straddle Price
- $10.00
- P/C Vol Ratio
- 5.40
- Market Cap
- $13.5B
- Open
- $138.10
- Day Range
- $137.58 – $141.45
- Volume
- 663,433
- Prev Close
- $137.54
Fair Value
MODEL: SHORT
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 0.78 |
| Cost of Equity (CAPM) | 8.82% (VRP-adj) |
| WACC | 8.31% |
| Volatility Risk Premium | +24.5pp (IV − HV30) |
| Effective Tax Rate | 20.5% |
| Rev. Growth (YoY, DCF input) | +8.9% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.09 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.5B |
| Return on Equity (TTM) | 24.0% |
| Book / Price | 25.5% |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | 7.3% |
| Debt / Equity | 0.73 |
| Quality Score | 2/6 — normal (10y DCF) |
| Market-Implied Growth | +13.9% (reverse-DCF on current price) |
| SMA 50 | $124.65 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $128.59 |
| Bollinger Width / SMA20 | 21.0% (drives anchor stability) |
| Net Debt | $2.5B |
| Market Cap | $14B |
Peers used for multiples: ARGX, CHE, ELV, ENSG, HUM, LLY, UNH, UTHR
60-Day Conviction
60%
20-Day Fair Value
≈ by Dec 8, 2026
$140.06
α -0.4%
rank 47%
conviction
30%
40-Day Fair Value
≈ by Jan 6, 2027
$140.84
α +0.1%
rank 47%
conviction
6%
60-Day Fair Value
≈ by Feb 4, 2027
$137.25
α -2.4%
rank 47%
conviction
60%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $95.99 | 21% | |
| DDM (Gordon) | $27.19 | 0% | |
| Peer P/E | $174.79 | 10% | median 25.1× · 7 peers |
| Peer EV/EBITDA | $243.66 | 10% | median 16.2× · 7 peers |
| Peer P/B | $134.90 | 2% | median 3.8× · 7 peers |
| Peer P/S | $130.19 | 6% | median 1.9× · 7 peers |
| Market Anchor (SMA50) | $124.65 | 30% | stability 71% (BB-width) |
| Options Expected (B-L 30d) | $140.84 | 21% | 23 strikes · skew +1.02 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- SERVICES-HOSPITALS (8060) · industry map
- Exchange
- XNYS
- Market Cap
- $13.5B
- Employees
- 30,192
- List Date
- 1989-09-13
- CIK
- 0000785161
- Last Earnings
- Oct 28 after close · +7.7% vs ±8.3% expected
- Next Earnings
- ~Feb 4, 2027 (estimated)
- Headquarters
- Birmingham, AL
- Homepage
- https://www.encompasshealth.com
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals, which is the company's sole segment. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. The company's inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, co…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -2.36% | -7.22% | 5.03% | 5.78% | 8.08% | -11.13% | -0.30% |
| Feb | -0.90% | 7.42% | -10.58% | 1.92% | -0.44% | 14.97% | 2.06% |
| Mar | 2.45% | 7.11% | -3.75% | 11.29% | 1.49% | -10.48% | 1.35% |
| Apr | 2.77% | -3.94% | 18.58% | 0.18% | 15.51% | 2.69% | 5.96% |
| May | 1.60% | -3.96% | -3.52% | 4.24% | 4.28% | -1.52% | 0.19% |
| Jun | -9.15% | -13.34% | 8.68% | 2.63% | 1.47% | -1.61% | -1.89% |
| Jul | 4.38% | 8.77% | -1.67% | 8.88% | -8.56% | 9.26% | 3.51% |
| Aug | -6.78% | -4.18% | 7.70% | 0.03% | 12.19% | 6.88% | 2.64% |
| Sep | -5.60% | -7.11% | -5.40% | 3.62% | 2.68% | -0.46% | -2.04% |
| Oct | -13.97% | 15.83% | -6.14% | 3.89% | -8.57% | 14.14% | 0.86% |
| Nov | -9.81% | 5.96% | 4.17% | 4.07% | 0.13% | 2.51%* | 1.17% |
| Dec | 15.30% | 3.55% | 0.50% | -9.81% | -7.46% | -- | 0.42% |
| Total | -22.73% | 5.01% | 10.64% | 41.51% | 19.12% | 23.78% | 12.89% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $129.40
SMA 50: $125.05
SMA 200: $111.21
Current: $140.65
EMA 12: $134.38
EMA 26: $129.87
MACD: 4.5124 | Signal: 1.4217
BULLISH
ADX (14): 29.51
TREND
+DI: 36.22
−DI: 14.74
Momentum Oscillators
RSI (14): 66.94
NEUTRAL
Stoch %K: 84.97
Stoch %D: 86.83
Williams %R: -11.56
Volume & Volatility
BB Upper: $143.73
BB Lower: $115.08
NEUTRAL
OBV: 12,416,262
Vol SMA 20: 1,232,948
Vol ROC: -22.68%
ATR: $4.11
True Range: $3.91
HV 20: 44.8%
HV 30: 39.1%
HV 60: 29.1%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before EHC’s Oct 28 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL with a confidence level of 6/10
Key Drivers:
- Technical indicators suggest a strong uptrend, with MACD signaling bullish momentum
- Recent news headlines have been positive, with no major negative events reported
Primary Risks:
- High IV premium indicating potential for increased volatility
- Stock's beta is low, suggesting it may not move as much as the market
Investment Thesis: Encompass Health (EHC) appears to be in a strong uptrend, driven by technical indicators and positive recent news. However, high IV premiums and low stock volatility suggest there may be limited room for further gains.
Recent News Sentiment Impact: The positive recent news headlines have contributed to the stock's uptrend, with investors likely reacting positively to earnings beats and dividend declarations.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): Uptrend Medium-term (1-3 months): Uptrend Long-term (3-12 months): Uptrend
Support/Resistance Levels:
- Lower Bollinger Band: $104.39
- Middle Band: $115.90
- Upper Band: $127.41
- Key Moving Average levels:
- SMA 20: $115.90
- SMA 50: $108.70
- SMA 200: $106.88
Momentum Signals:
- RSI (14): 68.50 (neutral)
- MACD: Bullish crossover above signal line
- Bollinger Bands: Neutral, with price near the middle band
Volume Analysis:
- Volume SMA 20: 829739.25
- On-Balance Volume (OBV): 11198762.68
- Volume Rate of Change: -21.39% (suggesting low institutional interest)
News & Sentiment Analysis
Recent Headlines Summary:
- Three Encompass Health insiders selling shares after rate increase (neutral)
- CFO trimmed stake as shares jumped after earnings (positive)
- Healthcare added 35,200 jobs—three stocks positioned to benefit (positive)
- Encompass Health declares dividend on common stock (positive)
Sentiment Assessment: The overall sentiment is positive, with three out of five recent news headlines having a positive tone.
Catalyst Identification:
- No major catalysts identified in the near term
Market Narrative: The positive recent news headlines and technical indicators suggest that investors are reacting positively to Encompass Health's fundamentals. However, the high IV premium may indicate potential for increased volatility, which could impact the stock's performance.
Risk & Volatility Assessment
Risk Assessment:
- Beta: 0.09 (low risk relative to market)
- Volatility Regime:
- Current: Low
- Historical: Moderate (HV20 43.5%, HV30 39.2%, HV60 34.4%)
- Options Market Signals:
- IV Rank: 26.1% (Medium - shows if volatility is historically high/low)
- Current IV: 49.0%
- Expected Move: $7.95 (35 DTE), 7-DTE: $3.58
Downside Protection:
- Support levels: SMA 20 ($115.90), Lower Bollinger Band ($104.39)
Market Context & Positioning
Sector Performance: Healthcare sector has been performing well, with Encompass Health being a key player.
Institutional Activity: Low institutional interest suggests that investors may be taking a cautious approach to the stock.
Correlation Analysis: Encompass Health's correlation with the market is low (0.04), suggesting it may not move as much as the broader market.
Relative Valuation: The stock appears to be trading near its upper Bollinger Band, which could indicate limited room for further gains.
Key Levels & Action Items
Critical Price Levels:
- Lower Bollinger Band: $104.39
- Middle Band: $115.90
- Upper Band: $127.41
Breakout/Breakdown Levels: No major levels identified in the near term
Time-Sensitive Catalysts: No major catalysts identified in the near term
Risk Management:
- Stop-loss levels: Consider setting stop-loss orders around the SMA 20 ($115.90) or Lower Bollinger Band ($104.39)
- Position sizing considerations: Investors may want to consider reducing their position size due to high IV premiums and low stock volatility.
Generated
News
All EHC news →
Discharge growth and higher patient acuity drove adjusted EPS up 23.6% this quarter.
Earnings History
22 of 24 under expected move
Avg Expected Move
7.92%
Avg Actual Move
4.13%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-01-26 | After-Close | 12.23% | 4.05% | 0.33x | Within |
| 2021-04-27 | After-Close | 8.84% | 1.17% | 0.13x | Within |
| 2021-07-27 | After-Close | 7.30% | 0.15% | 0.02x | Within |
| 2021-10-27 | After-Close | 10.53% | 2.80% | 0.27x | Within |
| 2022-02-01 | After-Close | 8.30% | 2.51% | 0.30x | Within |
| 2022-04-27 | After-Close | 9.58% | 4.80% | 0.50x | Within |
| 2022-08-01 | After-Close | 7.34% | 0.43% | 0.06x | Within |
| 2022-10-26 | After-Close | 15.56% | 2.04% | 0.13x | Within |
| 2023-02-07 | After-Close | 5.52% | 2.70% | 0.49x | Within |
| 2023-04-27 | After-Close | 2.57% | 1.12% | 0.44x | Within |
| 2023-08-01 | After-Close | 5.35% | 5.09% | 0.95x | Within |
| 2023-10-26 | After-Close | 6.37% | 0.62% | 0.10x | Within |
| 2024-02-07 | After-Close | 5.58% | 0.95% | 0.17x | Within |
| 2024-04-24 | After-Close | 6.38% | 0.08% | 0.01x | Within |
| 2024-08-05 | After-Close | 5.69% | 5.56% | 0.98x | Within |
| 2024-10-28 | After-Close | 8.06% | 7.42% | 0.92x | Within |
| 2025-02-06 | After-Close | 8.27% | 1.28% | 0.15x | Within |
| 2025-04-24 | After-Close | 7.72% | 11.79% | 1.53x | Exceeded |
| 2025-08-04 | After-Close | 6.55% | 4.00% | 0.61x | Within |
| 2025-10-29 | After-Close | 8.28% | 7.02% | 0.85x | Within |
| 2026-02-05 | After-Close | 7.56% | 5.86% | 0.78x | Within |
| 2026-04-30 | After-Close | 8.80% | 7.48% | 0.85x | Within |
| 2026-08-05 | After-Close | 9.47% | 12.55% | 1.33x | Exceeded |
| 2026-10-28 | After-Close | 8.35% | 7.70% | 0.92x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
EHC Options Activity & IV Rank
EHC IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 27.4%
7-DTE IV: 30.2%
Expected Move: $10.00
7-DTE Move: $5.97
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 523
Put Volume: 2,825
P/C Volume: 5.402
BEARISH
Call OI: 1,898
Put OI: 3,785
P/C OI: 1.994
Total OI: 5,683
ATM Options Pricing
ATM Call: $5.45
ATM Put: $4.55
Call %: 3.9%
Put %: 3.2%
Chain Summary
Chain Volume: 3,348
Chain OI: 5,683
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 21st percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
21%
vs own history
GEX tilt
+0.09
OI-weighted, today
Vanna tilt
+0.57
δ-sensitivity to IV
Charm tilt
-0.81
δ-decay vs time
Vanna tilt +0.57: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.81: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 23 ATM contracts, 4k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)19.6LowNov 9
IV Rank (30 DTE)19.1LowNov 9
Straddle Price (30 DTE)$10.00Nov 9
Beta Analysis
Risk Metrics
Beta: -0.0148
Alpha: 24.69%
Correlation: -0.0067
R-Squared: 0.0%
Stock Volatility: 30.5%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Negative beta - stock moves opposite to market
Negative beta - stock moves opposite to market
Beta & Alpha Over Time
Notable investors who own EHC
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $259.1M | #130 of 6285 | +400.7% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $81.4M | #411 of 3716 | +68.6% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $17.6M | #766 of 3138 | -34.2% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $4.1M | #517 of 997 | -11.6% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $422K | #2178 of 4729 | -3.3% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
EHC Institutional Ownership (13F)
Filings for 2026-06-30 · 307 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 100,600,000 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
6 filers$9.19M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $3.45M | 37.51% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $3.30M | 35.86% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $1.67M | 18.15% | 2026-06-30 |
| 4 | SIG BROKERAGE, LP | $505.40K | 5.50% | 2026-06-30 |
| 5 | Walleye Capital LLC | $262.81K | 2.86% | 2026-06-30 |
| 6 | Walleye Trading LLC | $10.11K | 0.11% | 2026-06-30 |
7 filers$9.69M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $2.69M | 27.74% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $2.62M | 27.01% | 2026-06-30 |
| 3 | Walleye Trading LLC | $2.55M | 26.28% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $960.26K | 9.91% | 2026-06-30 |
| 5 | SIG BROKERAGE, LP | $505.40K | 5.21% | 2026-06-30 |
| 6 | Walleye Capital LLC | $212.27K | 2.19% | 2026-06-30 |
| 7 | Twin Tree Management, LP | $161.73K | 1.67% | 2026-06-30 |
EHC Insider Trading (Form 4)
Latest: 2026-10-19Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-19 | Kevin J. O'Connor | Director | Award (A) | +18 | — | EDGAR | |
| 2026-10-19 | Edward M Christie III | Director | Award (A) | +232 | $126.63 | $28.0K | EDGAR |
| 2026-10-19 | Joan E Herman | Director | Award (A) | +81 | — | EDGAR | |
| 2026-10-19 | Cain A Hayes | Director | Award (A) | +4 | — | EDGAR | |
| 2026-10-19 | Terrance Williams | Director | Award (A) | +28 | — | EDGAR | |
| 2026-10-19 | Nancy M Schlichting | Director | Award (A) | +38 | — | EDGAR | |
| 2026-10-19 | Greg D Carmichael | Director | Award (A) | +28 | — | EDGAR | |
| 2026-10-19 | Christopher R Reidy | Director | Award (A) | +304 | $126.89 | $36.0K | EDGAR |
| 2026-10-19 | Leslye G Katz | Director | Award (A) | +81 | — | EDGAR | |
| 2026-09-01 | John Patrick Darby | EVP, Gen Counsel & Secretary | Mixed Exer +4,858 · Sell −4,858 |
— | $78.07 | -$417.9K | EDGAR |
| 2026-09-01 | Andrew L Price | Chief Accounting Officer | Sell (S) | −5,211 | $120.93 | -$630.2K | EDGAR |
| 2026-08-11 | Douglas E Coltharp | EVP & Chief Financial Officer | Sell (S) | −18,869 | $125.38 | -$2.37M | EDGAR |
| 2026-08-11 | Mark J Tarr | President & CEO | Sell (S) | −173,148 | $125.47 | -$21.72M | EDGAR |
| 2026-08-11 | John Patrick Darby | EVP, Gen Counsel & Secretary | Sell (S) | −8,906 | $125.95 | -$1.12M | EDGAR |
| 2026-07-16 | Kevin J. O'Connor | Director | Award (A) | +19 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
EHC Insider Holdings
17 insiders · @ $140.65
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Mark J Tarr | President & CEO | 267,814 | $37.67M | -$67.41M | 48 | 2026-08-11 |
| 2 | Edmund Fay | Sr. Vice Pres. and Treasurer | 89,325 | $12.56M | -$1.28M | 33 | 2026-03-10 |
| 3 | Douglas E Coltharp | EVP & Chief Financial Officer | 77,988 | $10.97M | -$14.98M | 52 | 2026-08-11 |
| 4 | John Patrick Darby | EVP, Gen Counsel & Secretary | 75,041 | $10.55M | -$4.08M | 44 | 2026-09-01 |
| 5 | Andrew L Price | Chief Accounting Officer | 69,483 | $9.77M | -$2.58M | 35 | 2026-09-01 |
| 6 | Leslye G Katz | Director | 49,724 | $6.99M | $0 | 46 | 2026-10-19 |
| 7 | Joan E Herman | Director | 49,724 | $6.99M | $0 | 46 | 2026-10-19 |
| 8 | Patrick William Tuer | EVP, Chief Operating Officer | 24,755 | $3.48M | -$499.1K | 8 | 2026-05-12 |
| 9 | Nancy M Schlichting | Director | 23,010 | $3.24M | $0 | 44 | 2026-10-19 |
| 10 | Greg D Carmichael | Director | 20,377 | $2.87M | $267.5K | 39 | 2026-10-19 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
EHC Board & Officers
As of SEC filings through Oct 19, 2026Directors 10
- Joan E Herman · since Jan 25, 2013
- Leslye G Katz · since Jan 25, 2013
- Mark J Tarr · listed since Jan 2017
- Nancy M Schlichting · since Dec 11, 2017
- Greg D Carmichael · since Jan 1, 2020
- Terrance Williams · since Jan 1, 2020
- Christopher R Reidy · since Oct 1, 2021
- Kevin J. O'Connor · since Mar 30, 2022
- Edward M Christie III · since Nov 27, 2023
- Cain A Hayes · since Jan 30, 2026
Officers 7
- Mark J Tarr · President & CEO · listed since Jan 2017
- Douglas E Coltharp · EVP & Chief Financial Officer · since May 6, 2010
- Patrick William Tuer · EVP, Chief Operating Officer · since Apr 24, 2025
- Andrew L Price · Chief Accounting Officer · listed since Feb 2010
- Elissa Joy Charbonneau · Chief Medical Officer · since Jul 1, 2015
- John Patrick Darby · EVP, Gen Counsel & Secretary · since Feb 8, 2016
- Edmund Fay · Sr. Vice Pres. and Treasurer · since May 8, 2008
Changes in the last 10 years (20)
| Jan 30, 2026 | Cain A Hayes became a director |
| Sep 17, 2025 | The company announced the departure of Patricia Anne Maryland from the board in an SEC filing |
| Apr 24, 2025 | Patrick William Tuer became EVP, Chief Operating Officer |
| Nov 27, 2023 | Edward M Christie III became a director |
| Jan 13, 2023 | Barbara Ann Jacobsmeyer reported in an SEC filing no longer being President & CEO, HHH |
| Mar 30, 2022 | Kevin J. O'Connor became a director |
| Jan 5, 2022 | Barbara Ann Jacobsmeyer listed as President & CEO, HHH (previously President, Inpatient Hospitals) in SEC filings |
| Oct 1, 2021 | Christopher R Reidy became a director |
| Jun 21, 2021 | April Kaye Bullock Anthony reported in an SEC filing no longer being CEO & President, Home Health |
| Jan 1, 2020 | Terrance Williams became a director |
| Jan 1, 2020 | Patricia Anne Maryland became a director |
| Jan 1, 2020 | Greg D Carmichael became a director |
| Mar 4, 2019 | April Kaye Bullock Anthony listed as CEO & President, Home Health (previously CEO and President, Encompass) in SEC filings |
| Feb 21, 2018 | Barbara Ann Jacobsmeyer listed as President, Inpatient Hospitals (previously EVP, Operations) in SEC filings |
| Dec 11, 2017 | Nancy M Schlichting became a director |
| Jan 5, 2017 | Mark J Tarr listed as President & CEO (previously EVP and COO) in SEC filings |
| Jan 5, 2017 | Mark J Tarr first listed as a director in an SEC filing |
| Jan 3, 2017 | Jay Grinney reported in an SEC filing no longer being a director |
| Jan 3, 2017 | Jay Grinney reported in an SEC filing no longer being Pres & Chief Executive Officer |
| Dec 29, 2016 | Barbara Ann Jacobsmeyer became EVP, Operations |
Not reported recently (8)
- Donald L Correll · Last reported as a director in an SEC filing dated Apr 16, 2024
- John Chidsey · Last reported as a director in an SEC filing dated Apr 16, 2024
- Leo I Higdon Jr · Last reported as a director in an SEC filing dated Apr 20, 2022
- John E Jr D D S Maupin · Last reported as a director in an SEC filing dated Apr 20, 2022
- Yvonne M Curl · Last reported as a director in an SEC filing dated Apr 20, 2022
- Charles M Elson · Last reported as a director in an SEC filing dated Apr 20, 2022
- L Edward Shaw Jr · Last reported as a director in an SEC filing dated Apr 20, 2022
- Cheryl B. Levy · Last reported as Chief Human Resources Officer in an SEC filing dated Feb 26, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
EHC Proposed Insider Sales (Form 144)
Latest: 2026-08-31
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
4 filings
· $25.8M notice value
· 3 unique filers
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Mark Tarr (1, $21.7M) · Douglas Coltharp (1, $2.4M) · John Patrick Darby (2, $1.7M)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-31 | John Patrick Darby | Officer | 4,858 | $588.3K | 2026-08-31 | UBS Financial Services Inc | — | EDGAR |
| 2026-08-10 | Mark Tarr | Officer | 173,148 | $21.72M | 2026-08-10 | UBS Financial Services Inc | — | EDGAR |
| 2026-08-10 | John Patrick Darby | Officer | 8,906 | $1.12M | 2026-08-10 | UBS Financial Services Inc | — | EDGAR |
| 2026-08-10 | Douglas Coltharp | Officer | 18,869 | $2.37M | 2026-08-10 | UBS Financial Services Inc | — | EDGAR |
| 2026-05-15 | Douglas Edward Coltharp | Officer | 27,694 | $2.96M | 2026-05-15 | UBS Financial Services Inc | — | EDGAR |
| 2026-05-11 | Patrick Tuer | Officer | 682 | $71.3K | 2026-05-11 | UBS Financial Services Inc | — | EDGAR |
| 2026-02-11 | Mark Tarr | Officer | 150,000 | $16.74M | 2026-02-11 | UBS Financial Services Inc | — | EDGAR |
| 2026-02-10 | Patrick Tuer | Officer | 2,804 | $301.8K | 2026-02-10 | UBS Financial Services Inc | — | EDGAR |
| 2025-08-27 | Patrick Tuer | Officer | 1,020 | $126.1K | 2025-08-27 | UBS Financial Services Inc | — | EDGAR |
| 2025-05-20 | Mark Tarr | Officer | 118,384 | $14.38M | 2025-05-20 | UBS Financial Services Inc | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-06
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-06 | Regulation FD disclosure | EDGAR |
| 2026-10-28 | Earnings results · Regulation FD disclosure | EDGAR |
| 2026-08-13 | Other events | EDGAR |
| 2026-08-05 | Earnings results · Regulation FD disclosure | EDGAR |
| 2026-06-01 | Material agreement · New debt obligation | EDGAR |
| 2026-05-15 | Material agreement · Other events | EDGAR |
| 2026-05-11 | Shareholder vote results | EDGAR |
| 2026-04-30 | Earnings results · Regulation FD disclosure | EDGAR |
| 2026-03-10 | Material agreement · Agreement terminated · New debt obligation | EDGAR |
| 2026-02-05 | Earnings results · Regulation FD disclosure | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-02-26 | 0000785161-26-000081 | EDGAR |
| 2025-02-28 | 0000785161-25-000009 | EDGAR |
| 2024-02-28 | 0000785161-24-000009 | EDGAR |
| 2023-02-27 | 0000785161-23-000012 | EDGAR |
| 2022-02-25 | 0000785161-22-000008 | EDGAR |
| 2021-02-26 | 0000785161-21-000006 | EDGAR |
| 2020-02-27 | 0000785161-20-000011 | EDGAR |
| 2019-02-27 | 0000785161-19-000011 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-11-03 | 0000785161-26-000239 | EDGAR |
| 2026-08-07 | 0000785161-26-000186 | EDGAR |
| 2026-05-01 | 0000785161-26-000130 | EDGAR |
| 2025-10-31 | 0000785161-25-000115 | EDGAR |
| 2025-08-06 | 0000785161-25-000052 | EDGAR |
| 2025-05-01 | 0000785161-25-000021 | EDGAR |
| 2024-11-01 | 0000785161-24-000050 | EDGAR |
| 2024-08-06 | 0000785161-24-000043 | EDGAR |
| 2024-05-02 | 0000785161-24-000028 | EDGAR |
| 2023-11-01 | 0000785161-23-000070 | EDGAR |
ETF Holders
159 ETFs hold EHC
25 shown · $2.26B total exposure · 0.22% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJH iShares Core S&P Mid-Cap ETF | iShares (BlackRock) | 0.40% | $491.0M | $121.4B | 2026-11-06 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.02% | $378.8M | — | 2026-09-30 |
| 3 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.15% | $269.8M | — | 2026-09-30 |
| 4 | VBR Vanguard Morningstar Small-Cap Value ETF | Vanguard | 0.27% | $175.6M | — | 2026-09-30 |
| 5 | VXF Vanguard Extended Market ETF | Vanguard | 0.14% | $134.9M | — | 2026-09-30 |
| 6 | MDY State Street® SPDR® S&P MIDCAP 400® ETF Trust | SPDR (State Street) | 0.42% | $106.4M | $25.6B | 2026-11-05 |
| 7 | IJK iShares S&P Mid-Cap 400 Growth ETF | iShares (BlackRock) | 0.81% | $82.8M | $10.2B | 2026-11-06 |
| 8 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.24% | $80.7M | — | 2026-11-05 |
| 9 | SPMD State Street® SPDR® Portfolio S&P 400™ Mid Cap ETF | SPDR (State Street) | 0.42% | $76.5M | $18.3B | 2026-11-05 |
| 10 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.07% | $59.5M | — | 2026-11-05 |
| 11 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.10% | $57.8M | $56.9B | 2026-11-06 |
| 12 | AVLV Avantis U.S. Large Cap Value ETF | Avantis | 0.23% | $52.1M | $22.2B | 2026-11-05 |
| 13 | VHT Vanguard Health Care ETF | Vanguard | 0.17% | $36.8M | — | 2026-09-30 |
| 14 | SCHM Schwab U.S. Mid-Cap ETF | Nport | 0.22% | $33.0M | — | 2026-08-31 |
| 15 | IWD iShares Russell 1000 Value ETF | iShares (BlackRock) | 0.04% | $29.7M | $82.9B | 2026-11-06 |
| 16 | IHF iShares U.S. Healthcare Providers ETF | iShares (BlackRock) | 1.68% | $25.6M | $1.5B | 2026-11-06 |
| 17 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.06% | $24.2M | — | 2026-11-05 |
| 18 | MDYG State Street® SPDR® S&P 400™ Mid Cap Growth ETF | SPDR (State Street) | 0.85% | $22.9M | $2.7B | 2026-11-05 |
| 19 | IVOO Vanguard S&P Mid-Cap 400 ETF | Vanguard | 0.35% | $20.0M | — | 2026-09-30 |
| 20 | IWS iShares Russell Mid-Cap Value ETF | iShares (BlackRock) | 0.13% | $19.4M | $14.8B | 2026-11-06 |
| 21 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.02% | $17.5M | $93.2B | 2026-11-06 |
| 22 | FXH First Trust Health Care AlphaDEX® Fund | First Trust | 1.44% | $16.8M | $1.2B | 2026-11-06 |
| 23 | OUSM ALPS | OShares U.S. Small-Cap Quality Dividend ETF | Nport | 1.97% | $16.6M | — | 2026-08-31 |
| 24 | OSCV Opus Small Cap Value ETF | Nport | 2.13% | $15.1M | — | 2026-07-31 |
| 25 | BGDV Bahl & Gaynor Dividend ETF | Nport | 1.84% | $14.8M | — | 2026-06-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
22.01
TTM Diluted EPS
$6.39
TTM Revenue
$6.34B
TTM Net Income
$642.90M
TTM Op. Cash Flow
—
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $1.61B | $149.90M | $1.50 | — |
| Q1 '26 | 2026-03-31 | $1.59B | $194.50M | $1.93 | $313.10M |
| Q4 '25 | 2025-12-31 | $1.54B | $144.60M | $1.43 | $346.00M |
| Q3 '25 | 2025-09-30 | $1.48B | $126.50M | $1.24 | $270.80M |
| Q2 '25 | 2025-06-30 | $1.46B | $142.10M | $1.39 | $270.20M |
| Q1 '25 | 2025-03-31 | $1.46B | $151.50M | $1.48 | $288.60M |
| Q4 '24 | 2024-12-31 | $1.41B | $118.10M | $1.18 | $278.80M |
| Q3 '24 | 2024-09-30 | $1.35B | $108.20M | $1.06 | $267.80M |
| Q2 '24 | 2024-06-30 | $1.30B | $114.10M | $1.12 | $217.40M |
| Q1 '24 | 2024-03-31 | $1.32B | $112.50M | $1.10 | $238.80M |
| Q4 '23 | 2023-12-31 | $1.25B | $87.00M | $0.85 | $201.00M |
| Q3 '23 | 2023-09-30 | $1.21B | $84.70M | $0.84 | $215.20M |
Q3 2026 • period ending 2026-09-30 • filed 2026-11-03
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
22.01
P/B
4.33
P/S
2.36
EV/EBITDA
11.76
EV/Sales
2.76
ROE
18.4%
ROA
8.3%
Div Yield
0.00%
FCF Yield
8.38%
Debt/Equity
0.77
Current Ratio
—
Market Cap
$14.32B
as of 2026-11-09
EHC vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.21T | 46.0 | +45.5% | +31.3% | 27 |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delawar | $353.2B | 30.0 | +9.7% | +18.3% | 44 |
| ELV Elevance Health, Inc. | $92.0B | 17.9 | +3.6% | +18.5% | 31 |
| ARGX argenx SE American Depositary Shares | $58.3B | — | — | +14.7% | 57 |
| HUM Humana Inc. | $52.1B | 40.9 | +18.5% | +63.8% | 9 |
| UTHR United Therapeutics Corp | $23.9B | 22.1 | +1.9% | +17.6% | 26 |
| EHC Encompass Health Corporation Common Stoc | $13.5B | 22.0 | +9.4% | +32.2% | 19 |
| ENSG The Ensign Group, Inc. | $10.6B | 27.0 | +17.5% | +4.3% | 20 |
| CHE Chemed Corporation | $6.8B | 25.8 | +5.2% | +27.4% | 52 |
| Peer median | $55.2B | 27.0 | +9.7% | +18.4% | 29 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
3.31M
SI % of Float
3.39%
Days to Cover
3.52
Short Vol Ratio
55.4%
Free Float
97.62M
Float %
99.0%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-09-22